Edition:
United States

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

39.26USD
11:53am EDT
Change (% chg)

$0.86 (+2.24%)
Prev Close
$38.40
Open
$38.25
Day's High
$39.37
Day's Low
$36.38
Volume
16,954
Avg. Vol
77,830
52-wk High
$41.90
52-wk Low
$12.04

Chart for

About

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38... (more)

Overall

Beta: --
Market Cap(Mil.): $1,235.51
Shares Outstanding(Mil.): 31.79
Dividend: --
Yield (%): --

Financials

  GTHX.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -2.40 -- --
ROI: -88.38 -0.71 13.13
ROE: -456.98 -2.76 14.96

BRIEF-G1 Therapeutics Files For Offering Of 3 Mln Shares

* FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK Source text: (http://bit.ly/2D2beLO) Further company coverage:

Mar 05 2018

BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer

* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER

Mar 05 2018

BRIEF-G1 Therapeutics Qtrly Net Loss Per Share $0.60

* G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

Feb 21 2018

BRIEF-Medimmune Ventures Sells 133,906 Shares Of G1 Therapeutics Inc's Common Stock On Dec 1

* MEDIMMUNE VENTURES INC REPORTS SALE OF 133,906 SHARES OF G1 THERAPEUTICS INC'S COMMON STOCK ON DEC 1 AT $19.75 PER SHARE - SEC FILING Source text: (http://bit.ly/2iVgOvs) Further company coverage:

Dec 05 2017

BRIEF-G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer

* G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER

Nov 28 2017

BRIEF-G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development​

* G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development​

Nov 08 2017

BRIEF-G1 Therapeutics qtrly ‍loss per share $0.55

* G1 therapeutics reports third quarter 2017 financial results and recent operational highlights

Nov 08 2017

Earnings vs. Estimates